Background:Multidisciplinary chronic kidney disease (CKD) clinics improve patient outcomes but their optimal design is unclear.Objective:To perform a scoping review to identify and describe current practices (structure, function) associated with multidisciplinary CKD clinics.Design:Scoping review.Setting:Databases included Medline, EMBASE, Cochrane, and CINAHL.Patients:Patients followed in multidisciplinary CKD clinics globally.Measurements:Multidisciplinary CKD clinic composition, entry criteria, follow-up, and outcomes.Methods:We systematically searched the literature to identify randomized controlled trials, non-randomized interventional studies, or observational studies of multidisciplinary CKD clinics defined by an outpatient setting where two or more allied health members (with or without a nephrologist) provided longitudinal care to 50 or more adult or pediatric patients with CKD. Included studies were from 2002 to present. Searches were completed on August 10, 2018. Title, abstracts, and full texts were screened independently by two reviewers with disagreements resolved by a third. We abstracted data from included studies to summarize multidisciplinary CKD clinic team composition, entry criteria, follow-up, and processes.Results:40 studies (8 randomized controlled trials and 32 non-randomized interventional studies or observational studies) involving 23 230 individuals receiving multidisciplinary CKD care in 12 countries were included. Thirty-eight focused on adults (27 with CKD, 10 incident dialysis patients, one conservative therapy) while two studies focused on adolescents or children with CKD. The multidisciplinary team included a mean of 4.6 (SD 1.5) members consisting of a nephrologist, nurse, dietician, social worker, and pharmacist in 97.4%, 86.8%, 84.2%, 57.9%, and 42.1% of studies respectively. Entry criteria to multidisciplinary CKD clinics ranged from glomerular filtration rates of 20 to 70 mL/min/1.73m2 or CKD stages 1 to 5 without any proteinuria or risk equation-based criteria. Frequency of follow-up was variable by severity of kidney disease. Team member roles and standardized operating procedures were infrequently reported.Limitations:Unstandardized definition of multidisciplinary CKD care, studies limited to CKD defined by glomerular filtration rate, and lack of representation from countries other than Canada, Taiwan, the United States, and the United Kingdom.Conclusions:There is heterogeneity in multidisciplinary CKD team composition, entry criteria, follow-up, and processes with inadequate reporting of this complex intervention. Additional research is needed to determine the best model for multidisciplinary CKD clinics.Trial registration:Not applicable.

No abstract

Objectives Existing Canadian social determinants of health (SDOH) indicators do not quantify uncertainty to identify priority areas. The objectives of this methodologic study were: (1) to estimate and map small area (dissemination area) shared and variable-specific SDOH indicators with measures of uncertainty using a Bayesian model that accounts for spatial dependence; (2) to quantify geographic variation in the SDOH indicators and their contribution to a shared indicator; and (3) to assess the SDOH indicators' associations with behavioural risk factors and their consistency with the Ontario Marginalization Index (ON-Marg). Methods Lower education-, income-, unemployment-, living alone-and visible minority-related variables used in existing Canadian SDOH indices were fit as dependent variables to a Bayesian model to produce area-based SDOH indicators that were mapped with measures of uncertainty in two study areas. The fractions of spatial variation explained by the model components were computed. Bayesian analysis of variance was used to examine the SDOH indicator associations with behavioural risk factors and their consistency with ON-Marg examined using Pearson's correlation coefficient. Results The shared component was strongly associated with material deprivation (i.e., income) in each study area; however, variable-specific SDOH indicators were important too. The SDOH indicators were associated with behavioural risk factors for chronic disease, particularly alcohol consumption and smoking, and the shared component estimates were consistent with the ON-Marg material deprivation. Conclusions The Bayesian approach to produce SDOH indicators met the three study objectives and as such provides a new approach to prioritize areas that may experience health inequalities. Résumé Objectifs Les indicateurs des déterminants sociaux de la santé canadiens existants ne quantifient pas l'incertitude pour déterminer les aires prioritaires. Voici les objectifs de cette étude méthodologique: 1) estimer et cartographier les indicateurs des déterminants sociaux de la santé communs et spécifiques à des variables de petites régions (aires de diffusion) en y intégrant des mesures de l'incertitude à l'aide d'un modèle bayésien qui tient compte de la dépendance spatiale; 2) quantifier la variation géographique des indicateurs des déterminants sociaux de la santé et leur contribution à l'établissement d'un indicateur commun; et, 3) évaluer les associations des indicateurs des déterminants sociaux de la santé avec les facteurs de risque comportementaux et leur conformité à l'indice de marginalisation ontarien (ON-Marg).

Background: Chronic kidney disease (CKD) affects up to 18% of those over the age of 65 years. Potentially inappropriate medication prescribing in people with CKD is common. Objectives: Develop a pragmatic list of medications used in primary care that required dose adjustment or avoidance in people with CKD, using a modified Delphi panel approach, followed by a consensus workshop. Methods: We conducted a comprehensive literature search to identify potential medications. A group of 17 experts participated in a 3-round modified Delphi panel to identify medications for inclusion. A subsequent consensus workshop of 8 experts reviewed this list to prioritize medications for the development of point-of-care knowledge translation materials for primary care. Results: After a comprehensive literature review, 59 medications were included for consideration by the Delphi panel, with a further 10 medications added after the initial round. On completion of the 3 Delphi rounds, 66 unique medications remained, 63 requiring dose adjustment and 16 medications requiring avoidance in one or more estimated glomerular filtration rate categories. The consensus workshop prioritized this list further to 24 medications that must be dose-adjusted or avoided, including baclofen, metformin, and digoxin, as well as the newer SGLT2 inhibitor agents. Conclusion and Relevance: We have developed a concise list of 24 medications commonly used in primary care that should be dose-adjusted or avoided in people with CKD to reduce harm. This list incorporates new and frequently prescribed medications and will inform an updated, easy to access source for primary care providers.